Algorae Pharmaceuticals says its new AI-168 drug candidate shows early potential to improve on treatments to protect the heart from cardiovascular stressors. Algorae Pharmaceuticals says its new AI-168 drug candidate shows early potential to improve on treatments to protect the heart from cardiovascular stressors. Business / Companies Sydney Morning Herald – Latest News
Algorae cardiovascular drug betters beta-blockers in studies
